Validation and Reproducibility Assessment of Tigecycline MIC Determinations by Etest
- 1 August 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (8) , 2474-2479
Abstract
A multicenter study was conducted to validate Etest tigecycline compared to the Clinical Laboratory Standards Institute reference broth microdilution and agar dilution methodologies. A large collection of gram-negative (n = 266) and gram-positive (n = 162) aerobic bacteria, a collection of anaerobes (n = 385), and selected collections of nonpneumococcal streptococci (n = 369), Streptococcus pneumoniae (n = 372), and Haemophilus influenzae (n = 372) were tested. Strains with reduced susceptibility to tigecycline were used with all test methods. The Etest showed excellent inter- and intralaboratory reproducibility for all organism groups tested regardless of the test methodology. The essential agreement values with the reference method (±1 dilution) were >99% for the collection of gram-negative and gram-positive aerobes; >98% for the S. pneumoniae, H. influenzae, and anaerobe collections; and 100% for the group of nonpneumococcal streptococci. These results validate the performance accuracy and utility of Etest tigecycline and verify the reproducibility of this convenient predefined gradient methodology for tigecycline susceptibility determination.Keywords
This publication has 15 references indexed in Scilit:
- Diagnostic PCR Analysis of the Occurrence of Methicillin and Tetracycline Resistance Genes among Staphylococcus aureus Isolates from Phase 3 Clinical Trials of Tigecycline for Complicated Skin and Skin Structure InfectionsAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activity of Tigecycline against Isolates from Patients Enrolled in Phase 3 Clinical Trials of Treatment for Complicated Skin and Skin‐Structure Infections and Complicated Intra‐Abdominal InfectionsClinical Infectious Diseases, 2005
- The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra‐Abdominal Infections: Analysis of Pooled Clinical Trial DataClinical Infectious Diseases, 2005
- The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin‐Structure Infections: Results of 2 Double‐Blind Phase 3 Comparison Studies with Vancomycin‐AztreonamClinical Infectious Diseases, 2005
- Effect of Medium Age and Supplementation with the Biocatalytic Oxygen-Reducing Reagent Oxyrase on In Vitro Activities of Tigecycline against Recent Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Tigecycline MIC Testing by Broth Dilution Requires Use of Fresh Medium or Addition of the Biocatalytic Oxygen-Reducing Reagent Oxyrase To Standardize the Test MethodAntimicrobial Agents and Chemotherapy, 2005
- BK Virus: Opportunity Makes a PathogenClinical Infectious Diseases, 2005
- In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)Diagnostic Microbiology and Infectious Disease, 2005
- Tigecycline: A review of preclinical and clinical studies of the first-in-class glycylcycline antibioticDrugs of Today, 2005
- Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936)Antimicrobial Agents and Chemotherapy, 2004